Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

In secondary prevention after an ASCVD event, what is the role of statins?

After an ASCVD event, the aim is to markedly lower the risk of another heart attack, stroke, or death. Statins achieve this by lowering LDL-C and also providing anti-inflammatory and plaque-stabilizing effects, which translate into fewer recurrent cardiovascular events. For most patients who can tolerate it, the recommended approach is high-intensity statin therapy, such as atorvastatin 40–80 mg or rosuvastatin 20–40 mg, with the goal of at least about a 50% reduction in LDL-C. If the LDL-C target isn’t reached or if there are tolerance issues, additional non-statin therapies like ezetimibe or PCSK9 inhibitors can be added to push risk down further. This is why the role of statins in secondary prevention is essential and not optional, and because the benefit applies regardless of the initial LDL-C level, there isn’t a specific LDL threshold (like >190) that determines necessity.

After an ASCVD event, the aim is to markedly lower the risk of another heart attack, stroke, or death. Statins achieve this by lowering LDL-C and also providing anti-inflammatory and plaque-stabilizing effects, which translate into fewer recurrent cardiovascular events. For most patients who can tolerate it, the recommended approach is high-intensity statin therapy, such as atorvastatin 40–80 mg or rosuvastatin 20–40 mg, with the goal of at least about a 50% reduction in LDL-C. If the LDL-C target isn’t reached or if there are tolerance issues, additional non-statin therapies like ezetimibe or PCSK9 inhibitors can be added to push risk down further. This is why the role of statins in secondary prevention is essential and not optional, and because the benefit applies regardless of the initial LDL-C level, there isn’t a specific LDL threshold (like >190) that determines necessity.